Chugai Pharmaceutical (OTCMKTS:CHGCY) Sets New 1-Year High – Should You Buy?

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY)’s share price reached a new 52-week high on Friday . The stock traded as high as $26.24 and last traded at $25.49, with a volume of 68174 shares changing hands. The stock had previously closed at $24.42.

Chugai Pharmaceutical Stock Performance

The company has a 50-day simple moving average of $22.06 and a two-hundred day simple moving average of $22.78. The firm has a market capitalization of $83.89 billion, a P/E ratio of 33.10 and a beta of 0.81.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.18 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 21.53% and a net margin of 33.07%. As a group, research analysts forecast that Chugai Pharmaceutical Co., Ltd. will post 0.74 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.